Kane Biotech Inc. (CVE:KNE – Get Free Report) shares traded down 33.3% during mid-day trading on Monday . The company traded as low as C$0.02 and last traded at C$0.02. 1,391,150 shares were traded during mid-day trading, an increase of 759% from the average daily volume of 161,896 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The stock has a fifty day moving average of C$0.03 and a two-hundred day moving average of C$0.03. The company has a market capitalization of C$4.10 million, a PE ratio of -2.00 and a beta of 1.05. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
